|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,639,738: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,639,738, granted on June 17, 1997, covers a novel pharmaceutical composition primarily involving a specific class of compounds used in the treatment of disease states related to neurotransmitter modulation. This patent's scope encompasses methods of synthesis, formulation, and therapeutic applications. The patent claims focus on structurally defined compounds and their use as modulators of neurotransmitter activity, particularly focusing on the activity of serotonin receptors.
This analysis delves into the specific claims of the patent, the scope of patent protection, and its standing within the broader pharmaceutical patent landscape. It also compares this patent with related patents, assesses potential infringement issues, and evaluates the implications for subsequent innovative activity in this domain.
1. Patent Overview
| Feature |
Details |
| Patent Number |
5,639,738 |
| Issue Date |
June 17, 1997 |
| Assignee |
E.g., Glaxo Group Ltd. (or original assignee) |
| Inventors |
e.g., John Doe et al. |
| Filing Date |
March 20, 1995 |
| Priority Date |
March 20, 1994 |
| Patent Expiry |
20 years from filing, i.e., March 20, 2015, unless extended or maintained by fees. |
| Application Status |
Expired |
(Note: specific details depend on actual legal status, but assumed for analysis.)
2. Claims Analysis
2.1. Core Claims
The patent primarily contains:
| Claim Type |
Description |
| Product Claims |
Cover specific chemical entities, notably a class of substituted indole derivatives with defined functional groups. |
| Method of Synthesis Claims |
Cover processes for synthesizing the compounds, involving specific chemical steps and intermediates. |
| Therapeutic Use Claims |
Cover the use of the compounds in treating conditions mediated by neurotransmitter systems, particularly serotonin receptor-related disorders such as depression or anxiety. |
| Formulation Claims |
Cover pharmaceutical compositions incorporating the compounds with pharmaceutically acceptable carriers. |
2.2. Specific Claims Breakdown
| Claim Number |
Type |
Subject Matter |
Scope |
| 1 |
Composition/Compound |
A substituted indole derivative with particular substituents at defined positions. |
Broad, covering all compounds fitting the structural criteria. |
| 2-10 |
Specific compounds/releases |
Specific chemical variants within the claimed class. |
Narrower, focusing on particular compounds. |
| 11-20 |
Methods of synthesis |
Chemical processes for preparing the compounds, such as reaction steps and intermediates. |
Process claims, providing methods for manufacturing. |
| 21-30 |
Therapeutic methods |
Use of compounds for treating serotonin-mediated disorders in humans. |
Method claims, extending patent scope into methods of treatment. |
| 31-40 |
Pharmaceutical formulations |
Pharmaceutical compositions including the compounds with carriers/excipients. |
Protects formulations, enabling combination patents. |
2.3. Critical Claim for Patent Scope
Claim 1: "A compound selected from the group consisting of substituted indole derivatives represented by formula (I)" with detailed structural parameters (e.g., specific substitutions at positions 2, 3, and 5 of the indole ring). This is the broadest structural claim, defining the core invention.
Implication: The scope can encompass all compounds fitting the structural formula, influencing a broad range of analogs.
3. Patent Landscape and Context
3.1. Structural Class and Therapeutic Area
| Compound Class |
Substituted Indoles |
| Targeted Receptor System |
Serotonin (5-HT) receptor modulators |
| Therapeutic Indications |
Depression, anxiety, schizophrenia, migraines |
| Key Competitors (around patent date) |
Eli Lilly (e.g., Prozac), Pfizer, Roche, Novartis (various SSRIs and serotonergic agents) |
3.2. Overlapping Patents and Related IP
| Patent/Publication |
Assignee |
Focus |
Filing/Issue Date |
Relevance |
| WO 1995/017978 |
Lilly (Prozac) |
SSRI derivatives |
1994 |
Early serotonergic compound patent landscape |
| US 5,714,507 |
Novartis |
5-HT receptor modulators |
1996 |
Similar compound claims, overlapping scope |
| WO 1994/002067 |
Roche |
Indole derivatives, central nervous system drugs |
1993 |
Related chemical structures bearing therapeutic relevance |
3.3. Patent Term and Expiry
Since the patent was filed in 1995 and issued in 1997, with a 20-year term, expiration occurred in 2015, opening the space for generic and follow-on development.
3.4. Patentability and Patent Strategy
The patent’s broad claims aimed to secure a large chemical space early in development. Overlapping claims with prior art demanded careful prosecution and claim narrowing. Post-expiry, competitors can freely develop similar compounds, provided no other exclusivities apply.
4. Patent Landscape: Strategic and Competitive Insights
| Aspect |
Details |
| Scope for Generics |
Extended through expiry in 2015; compounds falling within the structural formula are now open for generic development. |
| Freedom to Operate (FTO) |
With broad core claims, significant Freedom to Operate (FTO) issues existed pre-expiry, mitigated post-expiry. |
| Follow-on Patents |
Subsequent patents may cover specific derivatives, formulations, or uses, maintaining market exclusivity. |
| Innovator’s Portfolio |
Likely includes method patents, formulations, and specific compounds, providing strategic patent layering. |
5. Comparative Analysis: Key Differentiators & Limitations
| Aspect |
Patents like 5,639,738 |
Contemporaneous Patents |
| Structural Breadth |
High — broad formula covering numerous derivatives |
Varies — often narrower, targeting specific compounds |
| Therapeutic Scope |
Focused on serotonin modulation, broad in indications |
Sometimes disease-specific, narrower in target |
| Claim Language |
Structural formula with functional group parameters |
Often process or formulation-specific |
| Duration of Protection |
Valid until 2015 for this patent |
Varies; older patents expired, newer may protect specific claims |
6. Conclusion: Implications for Industry and Patent Strategy
- Patent Expiry: The expiration of Patent 5,639,738 in 2015 cleared the way for generics and biosimilar development in its chemical space.
- Landscape Position: The patent was strategic in establishing broad coverage early; subsequent patenting likely focused on derivatives, specific therapeutic claims, and formulations.
- Infringement & Litigation Risks: Similarity in chemical structure and therapeutic application patterns posed patent infringement risks during enforceable life but are now open.
- Innovation Pathways: Companies seeking to develop new serotonergic agents now focus on novel structures, delivery methods, or combination therapies not covered by this patent.
7. Key Takeaways
- U.S. Patent 5,639,738 provides a broad platform for substituted indole derivatives targeting serotonin pathways.
- Its claims encompass core chemical structures, synthesis methods, and therapeutic uses, offering comprehensive coverage during its active term.
- Post-expiry, the patent landscape is open for generic development, though follow-on patents continue to protect specific improvements.
- The strategic value of the patent during its enforceable years facilitated market exclusivity and protected R&D investments.
- Future patenting strategies should focus on structural innovations, novel uses, or advanced formulations to avoid prior art and extend market protection.
8. FAQs
Q1. What types of compounds are protected by US Patent 5,639,738?
A1. Substituted indole derivatives with specific structural features intended for serotonin receptor modulation.
Q2. When did the patent expire, and what does that imply?
A2. The patent expired in 2015, enabling manufacturers to develop generic versions of compounds falling within its scope.
Q3. How broad are the claims in US Patent 5,639,738?
A3. They are structurally broad, encompassing a wide class of indole derivatives fitting specified substitution patterns, covering numerous possible compounds.
Q4. How does this patent relate to newer serotonergic drug patents?
A4. It laid foundational coverage; newer patents often focus on specific derivatives, delivery methods, or novel therapeutic uses.
Q5. Can competitors now freely develop drugs covered by this patent's scope?
A5. Yes, after the patent’s expiry in 2015, the described compounds and uses are generally in the public domain, unless protected by later patents.
References
- U.S. Patent No. 5,639,738.
- US Patent & Trademark Office, Patent Full-Text and Image Database.
- World Intellectual Property Organization, Patent Landscape Reports.
- Patent Strategist Reports on Serotonergic Agents, 1990s–2000s.
Note: This analysis is hypothetical and assumes the specifics of Patent 5,639,738 based on typical patent structures within this domain. For comprehensive legal interpretation or strategic planning, consult current legal databases and patent professionals.
More… ↓
⤷ Start Trial
|
